Get started
Trulieve Cannabis CorporationTrulieve Cannabis CorporationTrulieve Cannabis Corporation

Trulieve Cannabis Corporation

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Bonds

TCNNF trade ideas

$TCNNF Trulieve Cannabis Corp Trade setupAverage analysts rating BUY with $25 price target Trulieve Cannabis Corp. engages in the provision of medical cannabis products. The firm cultivates and produces its products in-house and distributes to its branded stores, as well as directly to patients via home delivery. Its products include smokable flower, inhalation, oral, sublingual, topical, inter-nasal, and concentrates. The company was founded on September 21, 2018 and is headquartered in Quincy, FL.
OTC:TCNNFLong
by RedHotStocks
$TCNNF Trulieve CEO Fights back at Short SellerSource Benzinga Trulieve’s CEO Kim Rivers issued the following statement addressing the allegations: “We ask that our investors be aware that the Report reflects the opinions of an acknowledged short seller, whose sole interest is in profiting from a decline in the price of the Company’s shares. I have full confidence in our management team and their abilities to continue to serve our customers without being distracted by these baseless allegations. Trulieve reserves all of its rights to take appropriate legal action against those responsible for the Report.” Company profile Trulieve Cannabis Corp. engages in the provision of medical cannabis products. The firm cultivates and produces its products in-house and distributes to its branded stores, as well as directly to patients via home delivery. Its products include smokable flower, inhalation, oral, sublingual, topical, inter-nasal, and concentrates. The company was founded on September 21, 2018 and is headquartered in Quincy, FL.
OTC:TCNNFLong
by Bullishcharts
Trulieve Cannabis Corp Trulieve Cannabis Corp., together with its subsidiaries, operates as a medical marijuana company. Revenue is forecast to grow 39.46% per year. Earnings grew by 339.5% over the past year. RISK ANALYSIS Earnings are forecast to decline by an average of -14.4% per year for the next 3 years. High level of non-cash earnings. Highly volatile share price over past 3 months. Significant insider selling over the past 3 months. Disclaimer: We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and it is for entertainment purposes only.
CSE:TRUL
by CryptoTrend-Alerts